Aridis Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Aridis Pharmaceuticals has a total shareholder equity of $-11.8M and total debt of $3.4M, which brings its debt-to-equity ratio to -28.9%. Its total assets and total liabilities are $6.5M and $18.3M respectively.
Key information
-28.9%
Debt to equity ratio
US$3.41m
Debt
| Interest coverage ratio | n/a |
| Cash | US$35.00k |
| Equity | -US$11.80m |
| Total liabilities | US$18.34m |
| Total assets | US$6.53m |
Recent financial health updates
Recent updates
Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%
Sep 26Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M
Aug 16Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?
Feb 17
Aridis Pharmaceuticals EPS misses by $0.02
Nov 20Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow
Oct 31Financial Position Analysis
Short Term Liabilities: ARDS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ARDS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ARDS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ARDS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ARDS has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ARDS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.